PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31028998-0 2019 Metformin inhibits the proliferation of rheumatoid arthritis fibroblast-like synoviocytes through IGF-IR/PI3K/AKT/m-TOR pathway. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 98-104 31028998-6 2019 More importantly, metformin induced G2/M cell cycle phase arrest in RA-FLS via the IGF-IR/PI3K/AKT/ m-TOR pathway and inhibited m-TOR phosphorylation through both the IGF-IR/PI3K/AKT signaling pathways thereby further upregulating and down-regulating p70s6k and 4E-BP1 phosphorylation, respectively; however, metformin was found not to induce apoptosis in RA-FLSs. Metformin 18-27 insulin like growth factor 1 receptor Homo sapiens 83-89 31028998-6 2019 More importantly, metformin induced G2/M cell cycle phase arrest in RA-FLS via the IGF-IR/PI3K/AKT/ m-TOR pathway and inhibited m-TOR phosphorylation through both the IGF-IR/PI3K/AKT signaling pathways thereby further upregulating and down-regulating p70s6k and 4E-BP1 phosphorylation, respectively; however, metformin was found not to induce apoptosis in RA-FLSs. Metformin 18-27 insulin like growth factor 1 receptor Homo sapiens 167-173 31028998-8 2019 Moreover, IGF-IR/PI3K/AKT m-TOR signaling pathway can be regulated by metformin. Metformin 70-79 insulin like growth factor 1 receptor Homo sapiens 10-16 31205529-0 2019 Metformin Induces Apoptosis and Inhibits Proliferation through the AMP-Activated Protein Kinase and Insulin-like Growth Factor 1 Receptor Pathways in the Bile Duct Cancer Cells. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 100-137 31205529-11 2019 Metformin blocked the inhibitory effect of insulin-like growth factor 1 receptor (IGF-1R)/insulin receptor substrate 1 (IRS-1) pathway on TSC-2, and hyperglycemia impaired metformin-induced inhibition of IGF-1R/IRS-1 pathway and modulated the invasiveness of bile duct cancer cells; however, this effect was impaired by hyperglycemia. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 43-80 31205529-11 2019 Metformin blocked the inhibitory effect of insulin-like growth factor 1 receptor (IGF-1R)/insulin receptor substrate 1 (IRS-1) pathway on TSC-2, and hyperglycemia impaired metformin-induced inhibition of IGF-1R/IRS-1 pathway and modulated the invasiveness of bile duct cancer cells; however, this effect was impaired by hyperglycemia. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 82-88 31205529-11 2019 Metformin blocked the inhibitory effect of insulin-like growth factor 1 receptor (IGF-1R)/insulin receptor substrate 1 (IRS-1) pathway on TSC-2, and hyperglycemia impaired metformin-induced inhibition of IGF-1R/IRS-1 pathway and modulated the invasiveness of bile duct cancer cells; however, this effect was impaired by hyperglycemia. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 204-210 31205529-11 2019 Metformin blocked the inhibitory effect of insulin-like growth factor 1 receptor (IGF-1R)/insulin receptor substrate 1 (IRS-1) pathway on TSC-2, and hyperglycemia impaired metformin-induced inhibition of IGF-1R/IRS-1 pathway and modulated the invasiveness of bile duct cancer cells; however, this effect was impaired by hyperglycemia. Metformin 172-181 insulin like growth factor 1 receptor Homo sapiens 43-80 31205529-11 2019 Metformin blocked the inhibitory effect of insulin-like growth factor 1 receptor (IGF-1R)/insulin receptor substrate 1 (IRS-1) pathway on TSC-2, and hyperglycemia impaired metformin-induced inhibition of IGF-1R/IRS-1 pathway and modulated the invasiveness of bile duct cancer cells; however, this effect was impaired by hyperglycemia. Metformin 172-181 insulin like growth factor 1 receptor Homo sapiens 82-88 31205529-11 2019 Metformin blocked the inhibitory effect of insulin-like growth factor 1 receptor (IGF-1R)/insulin receptor substrate 1 (IRS-1) pathway on TSC-2, and hyperglycemia impaired metformin-induced inhibition of IGF-1R/IRS-1 pathway and modulated the invasiveness of bile duct cancer cells; however, this effect was impaired by hyperglycemia. Metformin 172-181 insulin like growth factor 1 receptor Homo sapiens 204-210 30025915-14 2018 Furthermore, metformin promoted AMP-activated protein kinase (AMPK) phosphorylation but inhibited insulin-like growth factor-1 receptor (IGF-1R) expression, protein kinase B (PKB/AKT) phosphorylation and mammalian target of rapamycin (mTOR) phosphorylation. Metformin 13-22 insulin like growth factor 1 receptor Homo sapiens 98-135 30025915-14 2018 Furthermore, metformin promoted AMP-activated protein kinase (AMPK) phosphorylation but inhibited insulin-like growth factor-1 receptor (IGF-1R) expression, protein kinase B (PKB/AKT) phosphorylation and mammalian target of rapamycin (mTOR) phosphorylation. Metformin 13-22 insulin like growth factor 1 receptor Homo sapiens 137-143 30154647-0 2018 Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway. Metformin 24-33 insulin like growth factor 1 receptor Homo sapiens 123-129 29241458-9 2017 IGF1, IGF1R, AKT p-IGF1, p-IGF1R, and p-Akt protein expression was enhanced dose-dependently with metformin, and was also significantly changed by treatment of CP70 cells with 0 mM metformin +10 mM LY294002. Metformin 98-107 insulin like growth factor 1 receptor Homo sapiens 6-11 29241458-9 2017 IGF1, IGF1R, AKT p-IGF1, p-IGF1R, and p-Akt protein expression was enhanced dose-dependently with metformin, and was also significantly changed by treatment of CP70 cells with 0 mM metformin +10 mM LY294002. Metformin 98-107 insulin like growth factor 1 receptor Homo sapiens 27-32 29241458-10 2017 Moreover, changes in the expression of MRP2, IGF1, IGF1R, and AKT was metformin-concentration dependent, and was significantly different from that in the untreated control group (P < 0.05). Metformin 70-79 insulin like growth factor 1 receptor Homo sapiens 51-56 29241458-12 2017 CONCLUSION: Metformin can improve the sensitivity of ovarian cancer CP70 cells to cisplatin in a concentration-dependent manner by activating the AKT signaling pathway, inhibiting the IGF1R signaling pathway, and reducing MRP2 expression. Metformin 12-21 insulin like growth factor 1 receptor Homo sapiens 184-189 28947975-1 2017 Reports suggest that metformin, a popular anti-diabetes drug, prevents breast cancer through various systemic effects, including insulin-like growth factor receptor (IGFR) regulation. Metformin 21-30 insulin like growth factor 1 receptor Homo sapiens 129-164 28947975-1 2017 Reports suggest that metformin, a popular anti-diabetes drug, prevents breast cancer through various systemic effects, including insulin-like growth factor receptor (IGFR) regulation. Metformin 21-30 insulin like growth factor 1 receptor Homo sapiens 166-170 27857021-9 2017 Further study revealed that metformin could suppress the expression of insulin-like growth factor 1 receptor and its downstream proteins, phosphoinositide 3-kinase (PI3K), protein kinase B (AKT/PKB), phosphorylation of AKT (pAKT), mammalian target of rapamycin (mTOR), p70S6K, and PKM2. Metformin 28-37 insulin like growth factor 1 receptor Homo sapiens 71-108 28253329-4 2017 Here, we seek to understand if metformin, a first line medication for the treatment of type 2 diabetes, inhibits the proliferation of benign prostatic epithelial cells through reducing the expression of IGF-1 receptor (IGF-1R) and regulating cell cycle. Metformin 31-40 insulin like growth factor 1 receptor Homo sapiens 203-217 28253329-4 2017 Here, we seek to understand if metformin, a first line medication for the treatment of type 2 diabetes, inhibits the proliferation of benign prostatic epithelial cells through reducing the expression of IGF-1 receptor (IGF-1R) and regulating cell cycle. Metformin 31-40 insulin like growth factor 1 receptor Homo sapiens 219-225 28253329-16 2017 CONCLUSIONS: Our study demonstrates that metformin inhibits the proliferation of benign prostatic epithelial cells by suppressing the expression of IGF-1R and IGF-1 secretion in stromal cells. Metformin 41-50 insulin like growth factor 1 receptor Homo sapiens 148-154 27488947-0 2016 Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 47-53 27488947-7 2016 Metformin could target IGF-1R signaling pathway by attenuating PI3K/AKT and MEK/ERK signaling pathways and down-regulating IGF-1R. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 23-29 27488947-7 2016 Metformin could target IGF-1R signaling pathway by attenuating PI3K/AKT and MEK/ERK signaling pathways and down-regulating IGF-1R. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 123-129 27488947-8 2016 Finally, we found that combining metformin with CP could further induce IGF-1R down-regulation and was more effective to target NSCLC cells. Metformin 33-42 insulin like growth factor 1 receptor Homo sapiens 72-78 27391065-5 2016 Metformin interferes with the proliferative autocrine loop of IGF2/IGF-1R, which supports adrenal cancer growth. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 67-73 27144340-3 2016 Metformin, a widely used antidiabetic agent, may reverse crizotinib resistance through inhibition of IGF-1R signaling. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 101-107 27144340-5 2016 Metformin reduced IGF-1R signaling activation in crizotinib-resistant cells. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 18-24 26706833-4 2016 Additionally, we assessed the added value of metformin as this drug may lower IGF1R stimulation. Metformin 45-54 insulin like growth factor 1 receptor Homo sapiens 78-83 26708419-9 2016 In addition, metformin reduced the phosphorylation of epidermal growth factor receptor (EGFR), particularly the phosphorylation of EGFR at Tyr845, and insulin-like growth factor 1 receptor (IGF-1R) in vitro and in vivo. Metformin 13-22 insulin like growth factor 1 receptor Homo sapiens 151-188 26708419-9 2016 In addition, metformin reduced the phosphorylation of epidermal growth factor receptor (EGFR), particularly the phosphorylation of EGFR at Tyr845, and insulin-like growth factor 1 receptor (IGF-1R) in vitro and in vivo. Metformin 13-22 insulin like growth factor 1 receptor Homo sapiens 190-196 26201966-12 2015 When stratified by metformin use, IGF-1R remained significantly elevated (P = 0.01) in men with PCa detected whereas p-AMPK (P = 0.05) was elevated only in those without PCa. Metformin 19-28 insulin like growth factor 1 receptor Homo sapiens 34-40 26201966-15 2015 The finding of IGF-1R elevation in positive PNBs versus p-AMPK elevation in negative PNBs suggests altered metabolic pathway activation precipitated by metformin use. Metformin 152-161 insulin like growth factor 1 receptor Homo sapiens 15-21 26287334-9 2015 We further illustrated the additive effect of metformin was likely through promoting further IGF-1R down-regulation. Metformin 46-55 insulin like growth factor 1 receptor Homo sapiens 93-99 25687657-9 2015 Higher concentrations of metformin lead to a significant (p < 0.05) dose-dependent attenuation of the progesterone effect with regard to IGFBP-1, -3, -5, -6, as well as IGF I receptor, while it did not change the expression of IGFBP-2 and -4, IGF I and II and the IGF II receptor. Metformin 25-34 insulin like growth factor 1 receptor Homo sapiens 172-186 25862373-0 2015 Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 99-136 25862373-6 2015 Accordingly, we examined the effects of metformin on IGF-1R signaling in prostate cancer cells. Metformin 40-49 insulin like growth factor 1 receptor Homo sapiens 53-59 25862373-11 2015 In addition, intraperitoneal treatment with metformin significantly reduced tumor growth and IGF-1R mRNA expression in PC-3 xenografts. Metformin 44-53 insulin like growth factor 1 receptor Homo sapiens 93-99 25862373-12 2015 Our results suggest that metformin is a potent inhibitor of the IGF-1/IGF-1R system and may be beneficial in prostate cancer treatment. Metformin 25-34 insulin like growth factor 1 receptor Homo sapiens 70-76 25305450-7 2015 Metformin inhibited the expression of insulin growth factor-I receptor (IGF-IR), and phosphatidyl inositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and the downstream mammalian target of rapamycin (mTOR). Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 38-70 25305450-7 2015 Metformin inhibited the expression of insulin growth factor-I receptor (IGF-IR), and phosphatidyl inositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and the downstream mammalian target of rapamycin (mTOR). Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 72-78 25305450-10 2015 We conclude that metformin inhibits MM cell proliferation through the IGF-1R/PI3K/AKT/mTOR signaling pathway. Metformin 17-26 insulin like growth factor 1 receptor Homo sapiens 70-76 25640355-0 2015 Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 89-95 25640355-4 2015 IGF-1R was highly expressed in human endometrial carcinoma paraffin sections, but IGF-1R and phosphor-protein kinase B/protein kinase B (p-Akt/ Akt) expression was down-regulated after metformin treatment (p<0.05). Metformin 185-194 insulin like growth factor 1 receptor Homo sapiens 82-88 25640355-5 2015 In summary, metformin can reduce the secretion of IGF-1 by Ishikawa and JEC EC cell lines and their expression of IGF-1R to deactivate downstream signaling involving the PI-3K/Akt pathway to inhibit endometrial carcinoma cell growth. Metformin 12-21 insulin like growth factor 1 receptor Homo sapiens 114-120 25289085-7 2014 Metformin was observed to downregulate IGF-1R and upregulate IGF binding protein-1 (IGFBP-1) mRNA and protein expression, while compound C, an adenosine monophosphate protein kinase inhibitor, reversed this effect. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 39-45 25289085-10 2014 Metformin combined with IGF-1R axis inhibitors may act synergistically to kill tumor cells, as metformin was shown to delay and prevent IGF-1R feedback. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 136-142 25289085-10 2014 Metformin combined with IGF-1R axis inhibitors may act synergistically to kill tumor cells, as metformin was shown to delay and prevent IGF-1R feedback. Metformin 95-104 insulin like growth factor 1 receptor Homo sapiens 24-30 25289085-10 2014 Metformin combined with IGF-1R axis inhibitors may act synergistically to kill tumor cells, as metformin was shown to delay and prevent IGF-1R feedback. Metformin 95-104 insulin like growth factor 1 receptor Homo sapiens 136-142 25143389-4 2014 Metformin and Sp knockdown by RNAi decreased expression of the insulin-like growth factor-1 receptor (IGF-1R), resulting in inhibition of mTOR signaling. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 63-100 25143389-4 2014 Metformin and Sp knockdown by RNAi decreased expression of the insulin-like growth factor-1 receptor (IGF-1R), resulting in inhibition of mTOR signaling. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 102-108 25143389-6 2014 Thus, the antineoplastic activities of metformin in pancreatic cancer are due, in part, to down-regulation of Sp TFs and Sp-regulated IGF-1R and EGFR, which in turn results in inhibition of mTOR and Ras signaling, respectively. Metformin 39-48 insulin like growth factor 1 receptor Homo sapiens 134-140 24627035-1 2014 OBJECTIVE: To assess the effect of metformin on gene and protein expression of insulin receptor (IR) and IGF-1 (IGF-1R) receptor in human endometrial stromal cells after stimulation with androgen and insulin. Metformin 35-44 insulin like growth factor 1 receptor Homo sapiens 105-110 24627035-1 2014 OBJECTIVE: To assess the effect of metformin on gene and protein expression of insulin receptor (IR) and IGF-1 (IGF-1R) receptor in human endometrial stromal cells after stimulation with androgen and insulin. Metformin 35-44 insulin like growth factor 1 receptor Homo sapiens 112-118 24437490-0 2014 Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 36-42 24437490-4 2014 We, therefore, evaluated whether metformin may affect androgen-dependent IGF-IR up-regulation. Metformin 33-42 insulin like growth factor 1 receptor Homo sapiens 73-79 24437490-5 2014 In the AR(+) LNCaP prostate cancer cells, we found that metformin inhibits androgen-induced CRE activity and IGF-IR gene transcription. Metformin 56-65 insulin like growth factor 1 receptor Homo sapiens 109-115 24437490-8 2014 Similarly to metformin action, CRTC2 silencing inhibited IGF-IR promoter activity. Metformin 13-22 insulin like growth factor 1 receptor Homo sapiens 57-63 24437490-11 2014 By inhibiting androgen-dependent IGF-IR up-regulation, metformin reduced IGF-I-mediated proliferation of LNCaP cells. Metformin 55-64 insulin like growth factor 1 receptor Homo sapiens 33-39 24437490-12 2014 These results indicate that, in prostate cancer cells, metformin inhibits IGF-I-mediated biological effects by disrupting membrane-initiated AR action responsible for IGF-IR up-regulation and suggest that metformin could represent a useful adjunct to the classical antiandrogen therapy. Metformin 55-64 insulin like growth factor 1 receptor Homo sapiens 167-173 24603137-3 2014 The aim of this study was to evaluate gene and protein expression of an insulin receptor (IR), insulin-like growth factor-1 (IGF1) receptor (IGF1R) and aromatase in granulosa cells treated with metformin and insulin. Metformin 194-203 insulin like growth factor 1 receptor Homo sapiens 95-139 24603137-3 2014 The aim of this study was to evaluate gene and protein expression of an insulin receptor (IR), insulin-like growth factor-1 (IGF1) receptor (IGF1R) and aromatase in granulosa cells treated with metformin and insulin. Metformin 194-203 insulin like growth factor 1 receptor Homo sapiens 141-146 24603137-6 2014 RESULTS: IR and IGF1R mRNA expression was significantly enhanced by metformin but was not affected by insulin. Metformin 68-77 insulin like growth factor 1 receptor Homo sapiens 16-21 24603137-9 2014 CONCLUSION: A direct effect of metformin on the gene expression of IGF1R, IR and aromatase was observed. Metformin 31-40 insulin like growth factor 1 receptor Homo sapiens 67-72 24107633-9 2013 Mechanisms of metformin action at normal vs. high glucose overlapped but were not identical; for example, metformin reduced IGF-1R expression in both the HER2+ SK-BR-3 and TNBC MDA-MB-468 cell lines more significantly at 5, as compared with 10 mmol/L glucose. Metformin 14-23 insulin like growth factor 1 receptor Homo sapiens 124-130 24107633-9 2013 Mechanisms of metformin action at normal vs. high glucose overlapped but were not identical; for example, metformin reduced IGF-1R expression in both the HER2+ SK-BR-3 and TNBC MDA-MB-468 cell lines more significantly at 5, as compared with 10 mmol/L glucose. Metformin 106-115 insulin like growth factor 1 receptor Homo sapiens 124-130 23663483-0 2013 Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 65-79 23663483-9 2013 The anti-proliferative actions of metformin were associated with an activation of AMP-activated protein kinase AMPKThr172 together with an inhibition of the insulin/insulin-like growth factor-I (IGF-I) receptor activation and downstream signalling mediators IRS-1 and phosphorylated Akt. Metformin 34-43 insulin like growth factor 1 receptor Homo sapiens 195-210 23620761-7 2013 Given the cross-talk between the insulin and IGF signaling pathways, the aim of this study was to examine the hypothesis that the anti-proliferative actions of metformin in uterine serous carcinoma (USC) are potentially mediated via suppression of the IGF-I receptor (IGF-IR) pathway. Metformin 160-169 insulin like growth factor 1 receptor Homo sapiens 252-266 23620761-7 2013 Given the cross-talk between the insulin and IGF signaling pathways, the aim of this study was to examine the hypothesis that the anti-proliferative actions of metformin in uterine serous carcinoma (USC) are potentially mediated via suppression of the IGF-I receptor (IGF-IR) pathway. Metformin 160-169 insulin like growth factor 1 receptor Homo sapiens 268-274 23141431-6 2012 Metformin with insulin significantly increased mRNA expressions of INSR, IGF-1R, and IRS-1, while metformin alone had no significant effect. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 73-79 22038047-4 2012 In Calu-1, but not in Calu-6 cells, metformin reduced phosphorylation of type 1 insulin-like growth factor receptor (IGF-IR) substrates Akt and Forkhead transcription factor 3a (FOXO3a), inhibited IGF1-dependent FOXO3a nuclear exit, and decreased IGF1-dependent cell proliferation. Metformin 36-45 insulin like growth factor 1 receptor Homo sapiens 117-123 21862872-10 2011 Metformin disrupts erbB2/IGF-1R complexes, erbB3 and IGF-1R expression and activity, as well as Src kinase and/or PI-3K/Akt signaling. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 25-31 21862872-10 2011 Metformin disrupts erbB2/IGF-1R complexes, erbB3 and IGF-1R expression and activity, as well as Src kinase and/or PI-3K/Akt signaling. Metformin 0-9 insulin like growth factor 1 receptor Homo sapiens 53-59 21597332-4 2011 Understanding how the IR/IGF-1R pathway functions in tumors is increasing in importance as the efficacy of drugs that target metabolic pathways, such as metformin, are investigated in prospective clinical trials. Metformin 153-162 insulin like growth factor 1 receptor Homo sapiens 25-31 19858375-0 2009 If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials. Metformin 23-32 insulin like growth factor 1 receptor Homo sapiens 87-124 19858375-0 2009 If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials. Metformin 157-166 insulin like growth factor 1 receptor Homo sapiens 87-124 35497918-0 2022 Correlation of Serum IGF-1R, VEGF, and ET Levels with Bone Mineral Density in Type 2 Diabetic Mellitus Patients Treated with Metformin Plus alpha-Glucosidase Inhibitors. Metformin 125-134 insulin like growth factor 1 receptor Homo sapiens 21-27 35427214-10 2022 Western blotting analyses demonstrated that the apoptosis-related protein of cleaved caspase 3 was activated; the expressions of Mcl-1, IGF-1R, PI3K, pAKT, and pmTOR proteins were inhibited by metformin in H929, RPMI8226, and MM.1s cells. Metformin 193-202 insulin like growth factor 1 receptor Homo sapiens 136-142 33007330-6 2021 In particular, we found that, in addition to AKT and ERK1/2 activation, FGFR1-induced activation of IRS1 and IGF1R, key regulators connecting metabolism and cancer, was associated with metformin resistance. Metformin 185-194 insulin like growth factor 1 receptor Homo sapiens 109-114 33007330-8 2021 Combination of NT157 with metformin induced enhanced inhibition of p-IGF1R, p-ERK1/2 and p-mTOR. Metformin 26-35 insulin like growth factor 1 receptor Homo sapiens 69-74 32982447-7 2020 In addition, metformin"s effects in the prevention and treatment for GC involve multiple pathways mainly via AMPK and IGF-1R. Metformin 13-22 insulin like growth factor 1 receptor Homo sapiens 118-124